The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy
Abstract
We have shown previously that the glucagon-like peptide-1 (GLP-1)-(7–36) amide increases myocardial glucose uptake and improves left ventricular (LV) and systemic hemodynamics in both conscious dogs with pacing-induced dilated cardiomyopathy (DCM) and humans with LV systolic dysfunction after acute myocardial infarction. However, GLP-1-(7–36) is rapidly degraded in the plasma to GLP-1-(9–36) by dipeptidyl peptidase IV (DPP IV), raising the issue of which peptide is the active moiety. By way of methodology, we compared the efficacy of a 48-h continuous intravenous infusion of GLP-1-(7–36) (1.5 pmol·kg−1·min−1) to GLP-1-(9–36) (1.5 pmol·kg−1·min−1) in 28 conscious, chronically instrumented dogs with pacing-induced DCM by measuring LV function and transmyocardial substrate uptake under basal and insulin-stimulated conditions using hyperinsulinemic-euglycemic clamps. As a result, dogs with DCM demonstrated myocardial insulin resistance under basal and insulin-stimulated conditions. Both GLP-1-(7–36) and GLP-1-(9–36) significantly reduced ( P < 0.01) LV end-diastolic pressure [GLP-1-(7–36), 28 ± 1 to 15 ± 2 mmHg; GLP-1-(9–36), 29 ± 2 to 16 ± 1 mmHg] and significantly increased ( P < 0.01) the first derivative of LV pressure [GLP-1-(7–36), 1,315 ± 81 to 2,195 ± 102 mmHg/s; GLP-1-(9–36), 1,336 ± 77 to 2,208 ± 68 mmHg] and cardiac output [GLP-1-(7–36), 1.5 ± 0.1 to 1.9 ± 0.1 l/min; GLP-1-(9–36), 2.0 ± 0.1 to 2.4 ± 0.05 l/min], whereas an equivolume infusion of saline had no effect. Both peptides increased myocardial glucose uptake but without a significant increase in plasma insulin. During the GLP-1-(9–36) infusion, negligible active (NH 2-terminal) peptide was measured in the plasma. In conclusion, in DCM, GLP-1-(9–36) mimics the effects of GLP-1-(7–36) in stimulating myocardial glucose uptake and improving LV and systemic hemodynamics through insulinomimetic as opposed to insulinotropic effects. These data suggest that GLP-1-(9–36) amide is an active peptide.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“GLP-1 agonists improve cardiac output and blood pressure (BP) in dogs with pacing-induced cardiomyopathy (28).”
From Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans (2008) · cites this paper as [28]
Citations
Cites
Nikolaidis, L. A., Mankad, S., Sokos, G. G., Miske, G., Shah, A., Elahi, D., & Shannon, R. P. (2004) · Circulation · doi:10.1161/01.cir.0000120505.91348.58 · Cited by 901
Self-citationGlucagon-like Peptide 1 Can Directly Protect the Heart Against Ischemia/Reperfusion Injury
Bose, A., Mocanu, M. M., Carr, R. D., Brand, C. L., & Yellon, D. M. (2005) · Diabetes · doi:10.2337/diabetes.54.1.146 · Cited by 644
Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor
Bullock, B. P., Heller, R. S., & Habener, J. F. (1996) · Endocrinology · doi:10.1210/endo.137.7.8770921 · Cited by 622
Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans
Holst, J. J., & Gromada, J. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00545.2003 · Cited by 611
The Multiple Actions of GLP-1 on the Process of Glucose-Stimulated Insulin Secretion
MacDonald, P. E., El-kholy, W., Riedel, M. J., Salapatek, A. M. F., Light, P. E., & Wheeler, M. B. (2002) · Diabetes · doi:10.2337/diabetes.51.2007.s434 · Cited by 590 · cited 3×
“There is a growing body of evidence supporting the efficacy of GLP-1-(7–36) amide as a potent stimulus to insulin release (insulinotropic) in Type 2 diabetes mellitus (10, 15, 19).”
Nikolaidis, L., Elahi, D., Hentosz, T., Doverspike, A., Huerbin, R., Zourelias, L., Stolarski, C. J., Shen, Y.-T., & Shannon, R. (2004) · Circulation · doi:10.1161/01.cir.0000139339.85840.dd · Cited by 546
Self-citationYamamoto, H., Lee, C. E., Marcus, J. N., Williams, T. D., Overton, J., Lopez, M. E., Hollenberg, A., Baggio, L., Saper, C., Drucker, D. J., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15595 · Cited by 544
Brubaker, P. L., & Drucker, D. J. (2004) · Endocrinology · doi:10.1210/en.2004-0015 · Cited by 537
Yamamoto, H., Lee, C. E., Marcus, J. N., Williams, T. D., Overton, J. M., Lopez, M. E., Hollenberg, A. N., Baggio, L., Saper, C. B., Drucker, D. J., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215595 · Cited by 429
Baggio, L. L., Huang, Q., Brown, T. J., & Drucker, D. J. (2004) · Diabetes · doi:10.2337/diabetes.53.9.2492 · Cited by 389
Cited by
Sorted by citations
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
Ban, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057
Cardiac Metabolism and its Interactions With Contraction, Growth, and Survival of Cardiomyocytes
Kolwicz, S. C., Purohit, S., & Tian, R. (2013) · Circulation Research · doi:10.1161/circresaha.113.302095 · Cited by 838
Heart Failure in Type 2 Diabetes Mellitus
Kenny, H., & Abel, E. D. (2019) · Circulation Research · doi:10.1161/circresaha.118.311371 · Cited by 682
The Cardiovascular Biology of Glucagon-like Peptide-1
Drucker, D. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.06.009 · Cited by 665
Noyan-Ashraf, M. H., Momen, M. A., Ban, K., Sadi, A.-M., Zhou, Y.-Q., Riazi, A. M., Baggio, L. L., Henkelman, R. M., Husain, M., & Drucker, D. J. (2009) · Diabetes · doi:10.2337/db08-1193 · Cited by 575
Cardiovascular Biology of the Incretin System
Ussher, J. R., & Drucker, D. J. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1052 · Cited by 534
The incretin system and its role in type 2 diabetes mellitus
Holst, J. J., Vilsboll, T., & Deacon, C. F. (2008) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.08.012 · Cited by 528
Jaswal, J. S., Keung, W., Wang, W., Ussher, J. R., & Lopaschuk, G. D. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.01.015 · Cited by 401
Dipeptidyl Peptidase-4 Inhibition and the Treatment of Type 2 Diabetes
Drucker, D. J. (2007) · Diabetes Care · doi:10.2337/dc07-0228 · Cited by 367
Cardiovascular Actions of Incretin-Based Therapies
Ussher, J. R., & Drucker, D. J. (2014) · Circulation Research · doi:10.1161/circresaha.114.301958 · Cited by 358
Sonne, D. P., Engstrøm, T., & Treiman, M. (2007) · Regulatory Peptides · doi:10.1016/j.regpep.2007.10.001 · Cited by 291
Regulation of Glucose Homeostasis by GLP-1
Nadkarni, P., Chepurny, O. G., & Holz, G. G. (2014) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-800101-1.00002-8 · Cited by 287
Sauvé, M., Ban, K., Momen, M. A., Zhou, Y., Henkelman, R. M., Husain, M., & Drucker, D. J. (2010) · Diabetes · doi:10.2337/db09-0955 · Cited by 264
Sokos, G. G., Bölükoglu, H., German, J., Hentosz, T. M., Magovern, G. J., Maher, T. D., Dean, D. A., Bailey, S. H., MARRONE, G. C., Benckart, D. H., et al. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.05.022 · Cited by 253
Self-citationErdogdu, Ö., Nathanson, D., Sjöholm, Å., Nyström, T., & Zhang, Q. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2010.04.022 · Cited by 234
Read, P. A., Khan, F. Z., Heck, P. M., Hoole, S. P., & Dutka, D. P. (2010) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.109.899377 · Cited by 226
Green, B. D., Flatt, P. R., & Bailey, C. J. (2006) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2006.024 · Cited by 233
Ban, K., Kim, K.-H., Cho, C.-K., Sauvé, M., Diamandis, E. P., Backx, P. H., Drucker, D. J., & Husain, M. (2010) · Endocrinology · doi:10.1210/en.2009-1197 · Cited by 232
Cardiovascular effects of DPP-4 inhibition: Beyond GLP-1
Fadini, G. P., & Avogaro, A. (2011) · Vascular Pharmacology · doi:10.1016/j.vph.2011.05.001 · Cited by 213
Hwang, I., Park, Y. J., Kim, Y.-R., Kim, Y. N., Ka, S., Lee, H., Seong, J. K., Seok, Y., & Kim, J. B. (2015) · The FASEB Journal · doi:10.1096/fj.14-265983 · Cited by 206
The Extrapancreatic Effects of Glucagon-Like Peptide-1 and Related Peptides
Abu‐Hamdah, R., Rabiee, A., Meneilly, G. S., Shannon, R. P., Andersen, D. K., & Elahi, D. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1296 · Cited by 203
Self-citationManandhar, B., & Ahn, J. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500810s · Cited by 203
On the origin of serum CD26 and its altered concentration in cancer patients
Cordero, O. J., Salgado, F. J., & Nogueira, M. (2009) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-009-0728-1 · Cited by 203
Chai, W., Dong, Z., Wang, N., Wang, W., Tao, L., Cao, W., & Liu, Z. (2012) · Diabetes · doi:10.2337/db11-1073 · Cited by 194
Dipeptidyl peptidase-4 inhibitors and heart failure: A meta-analysis of randomized clinical trials
Monami, M., Dicembrini, I., & Mannucci, E. (2014) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2014.01.017 · Cited by 192
New Drugs for the Treatment of Diabetes
Inzucchi, S. E., & McGuire, D. K. (2008) · Circulation · doi:10.1161/circulationaha.107.735795 · Cited by 188
Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes
Gautier, J. F., Choukem, S. P., & Girard, J. R. (2008) · Diabetes & Metabolism · doi:10.1016/s1262-3636(08)73397-4 · Cited by 186
Lepore, J. J., Olson, E., Demopoulos, L., Haws, T., Fang, Z., Barbour, A. M., Fossler, M., Davila-Roman, V. G., Russell, S. D., & Gropler, R. J. (2016) · JACC: Heart Failure · doi:10.1016/j.jchf.2016.01.008 · Cited by 165
Tarquini, R., Lazzeri, C., Pala, L., Rotella, C. M., & Gensini, G. F. (2010) · Acta Diabetologica · doi:10.1007/s00592-010-0180-x · Cited by 155
Green, B. D., Hand, K. V., Dougan, J. E., McDonnell, B. M., Cassidy, R. S., & Grieve, D. (2008) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2008.08.001 · Cited by 152
The effect of glucagon-like peptide 1 on cardiovascular risk
Sivertsen, J., Rosenmeier, J. B., Holst, J. J., & Vilsbøll, T. (2012) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.211 · Cited by 147
Targeting the glucagon receptor family for diabetes and obesity therapy
Cho, Y. M., Merchant, C. E., & Kieffer, T. J. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.05.009 · Cited by 144
Glucagon‐like peptide‐1‐based therapies and cardiovascular disease: looking beyond glycaemic control
Anagnostis, P. G., Athyros, V. G., Adamidou, F., Panagiotou, A., Kita, M. D., Karagiannis, A. I., & Mikhailidis, D. P. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01345.x · Cited by 143
Ussher, J. R., Baggio, L. L., Campbell, J. E., Mulvihill, E. E., Kim, M., Kabir, M. G., Cao, X., Baranek, B. M., Stoffers, D. A., Seeley, R. J., et al. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2014.04.009 · Cited by 144
Insulin-like actions of glucagon-like peptide-1: a dual receptor hypothesis
Tomás, E., & Habener, J. F. (2009) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2009.11.007 · Cited by 135
Vrang, N., & Larsen, P. J. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.07.003 · Cited by 139
GLP-1 and cardioprotection: from bench to bedside
Ravassa, S., Zudaire, A., & Díez, J. (2012) · Cardiovascular Research · doi:10.1093/cvr/cvs123 · Cited by 126
Targeting cell death in the reperfused heart: Pharmacological approaches for cardioprotection
Oerlemans, M. I. F. J., Koudstaal, S., Chamuleau, S. A. J., de Kleijn, D. P. V., Doevendans, P. A., & Sluijter, J. P. G. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.03.055 · Cited by 125
Bose, A., Mocanu, M. M., Carr, R. D., & Yellon, D. M. (2007) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-007-6030-6 · Cited by 123
Minireview: Update on Incretin Biology: Focus on Glucagon-Like Peptide-1
Brubaker, P. L. (2010) · Endocrinology · doi:10.1210/en.2010-0115 · Cited by 122
Incretins: their physiology and application in the treatment of diabetes mellitus
Tasyurek, H. M., Altunbas, H. A., Balci, M. K., & Sanlioglu, S. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2501 · Cited by 121
Grieve, D., Cassidy, R. S., & Green, B. D. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00376.x · Cited by 122
Phillips, L. K., & Prins, J. B. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2012.06491.x · Cited by 122
Yin, M., Silljé, H. H. W., Meissner, M., van Gilst, W. H., & de Boer, R. A. (2011) · Cardiovascular Diabetology · doi:10.1186/1475-2840-10-85 · Cited by 118
New insights into insulin action and resistance in the vasculature
Manrique, C. M., Lastra, G., & Sowers, J. R. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12395 · Cited by 121
Read, P. A., Khan, F. Z., & Dutka, D. P. (2011) · Heart · doi:10.1136/hrt.2010.219345 · Cited by 114
GLP-1 receptor agonists and atherosclerosis protection: the vascular endothelium takes center stage
Park, B., Bakbak, E., Teoh, H., Krishnaraj, A., Dennis, F., Quan, A., Rotstein, O. D., Butler, J., Hess, D. A., & Verma, S. (2024) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00574.2023 · Cited by 119
Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial
Holman, R. R., Bethel, M. A., George, J. T., Sourij, H., Doran, Z., Keenan, J. F., Khurmi, N. S., Mentz, R. J., Oulhaj, A., Buse, J. B., et al. (2015) · American Heart Journal · doi:10.1016/j.ahj.2015.12.009 · Cited by 105
Dipeptidyl Peptidase IV Inhibition Improves Cardiorenal Function in Overpacing-Induced Heart Failure
Gomez, N., Touihri, K., Matheeussen, V., Costa, A. M. D., Mahmoudabady, M., Mathieu, M., Baerts, L., Peace, A. J., Lybaert, P., Scharpé, S., et al. (2011) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfr146 · Cited by 106
Bao, W., Aravindhan, K., Alsaid, H., Chendrimada, T. P., Szapacs, M. E., Citerone, D. R., Harpel, M. R., Willette, R. N., Lepore, J. J., & Jucker, B. M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023570 · Cited by 106
Meier, J. J., Gethmann, A., Nauck, M. A., Götze, O., Schmitz, F., Deacon, C. F., Gallwitz, B., Schmidt, W. E., & Holst, J. J. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00576.2005 · Cited by 104
Bharucha, A. E., Charkoudian, N., Andrews, C. N., Camilleri, M., Sletten, D., Zinsmeister, A. R., & Low, P. A. (2008) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00153.2008 · Cited by 98
GLP‐1 (9–36) Amide, Cleavage Product of GLP‐1 (7–36) Amide, Is a Glucoregulatory Peptide
Elahi, D., Egan, J. M., Shannon, R. P., Meneilly, G. S., Khatri, A., Habener, J. F., & Andersen, D. K. (2008) · Obesity · doi:10.1038/oby.2008.229 · Cited by 104
Self-citationTomás, E., Stanojevic, V., & Habener, J. F. (2011) · Regulatory Peptides · doi:10.1016/j.regpep.2011.01.003 · Cited by 103
Glucagon-like peptide-1 receptor action in the vasculature
Almutairi, M., Al Batran, R., & Ussher, J. R. (2019) · Peptides · doi:10.1016/j.peptides.2018.09.002 · Cited by 99
Helmstädter, J., Keppeler, K., Küster, L., Münzel, T., Daiber, A., & Steven, S. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15462 · Cited by 99
Hausenloy, D. J., Whittington, H. J., Wynne, A. M., Begum, S. S., Theodorou, L., Riksen, N. P., Mocanu, M. M., & Yellon, D. M. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-154 · Cited by 96
Jiang, Y. Z., Rose, A. J., Sijmonsma, T., Bröer, A., Pfenninger, A., Herzig, S., Schmoll, D., & Bröer, S. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2015.02.003 · Cited by 96
Dissecting the Physiology and Pathophysiology of Glucagon-Like Peptide-1
Paternoster, S., & Falasca, M. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00584 · Cited by 92
Glucagon-like peptide 1-related peptides increase nitric oxide effects to reduce platelet activation
Barale, C., Buracco, S., Cavalot, F. L., Frascaroli, C., Guerrasio, A., & Russo, I. (2017) · Thrombosis and Haemostasis · doi:10.1160/th16-07-0586 · Cited by 93
Ban, K., Hui, S., Drucker, D. J., & Husain, M. (2009) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2009.04.001 · Cited by 85
Pabreja, K., Mohd, M. A., Koole, C., Wootten, D. L., & Furness, S. G. B. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12313 · Cited by 88
Cardiovascular Effects of Glucagonlike peptide–1 Agonists
Davidson, M. H. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.03.046 · Cited by 84
Hepatic functions of GLP-1 and its based drugs: current disputes and perspectives
Jin, T., & Weng, J. (2016) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00069.2016 · Cited by 87
Esposito, G., Cappetta, D., Russo, R., Rivellino, A., Ciuffreda, L. P., Roviezzo, F., Piegari, E., Berrino, L., Rossi, F., Angelis, A. D., et al. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13686 · Cited by 81
Zhang, L., Pang, X.-F., Bai, F., Wang, N.-P., Shah, A., McKallip, R. J., Li, X., Wang, X., & Zhao, Z. (2015) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-015-6592-7 · Cited by 83
Nuamnaichati, N., Mangmool, S., Chattipakorn, N., & Parichatikanond, W. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00805 · Cited by 83
The Ascending GLP-1 Road From Clinical Safety to Reduction of Cardiovascular Complications
Drucker, D. J. (2018) · Diabetes · doi:10.2337/dbi18-0008 · Cited by 81
Kim, B.-J., Zhou, J., Martin, B., Carlson, O. D., Maudsley, S. R., Greig, N. H., Mattson, M. P., Ladenheim, E. E., Wustner, J., Turner, A., et al. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.166470 · Cited by 78
Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure
Arturi, F., Succurro, E., Miceli, S., Cloro, C., Ruffo, M., Maio, R., Perticone, M., Sesti, G., & Perticone, F. (2016) · Endocrine · doi:10.1007/s12020-016-1166-4 · Cited by 75
Jokura, H., Watanabe, I., Umeda, M., Hase, T., & Shimotoyodome, A. (2015) · Nutrition Research · doi:10.1016/j.nutres.2015.07.005 · Cited by 73
Burgmaier, M., Liberman, A., Möllmann, J., Kahles, F., Reith, S., Lebherz, C., Marx, N., & Lehrke, M. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.08.033 · Cited by 73
Scalzo, R. L., Moreau, K. L., Ozemek, C., Herlache, L., McMillin, S. L., Gilligan, S., Huebschmann, A. G., Bauer, T. A., Dorosz, J. L., Reusch, J. E. B., et al. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.10.003 · Cited by 75
Proglucagon-Derived Peptides as Therapeutics
Lafferty, R. A., O'Harte, F. P. M., Irwin, N., Gault, V. A., & Flatt, P. R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.689678 · Cited by 76
Dong, Z., Chai, W., Wang, W., Zhao, L., Fu, Z., Cao, W., & Liu, Z. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00473.2012 · Cited by 71
Exenatide exerts a PKA-dependent positive inotropic effect in human atrial myocardium
Wallner, M., Kolesnik, E., Ablasser, K., Khafaga, M., Wakula, P., Ljubojević-Holzer, S., Thon-Gutschi, E., Sourij, H., Kapl, M., Edmunds, N. J., et al. (2015) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2015.09.018 · Cited by 74
Immunoassays for the incretin hormones GIP and GLP-1
Deacon, C. F., & Holst, J. J. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.03.006 · Cited by 66
Incretin‐based therapies – review of the physiology, pharmacology and emerging clinical experience
Martin, J. H., Deacon, C. F., Gorrell, M. D., & Prins, J. B. (2011) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2011.02439.x · Cited by 71
Vascular Biology of Glucagon Receptor Superfamily Peptides: Mechanistic and Clinical Relevance
Pujadas, G., & Drucker, D. J. (2016) · Endocrine Reviews · doi:10.1210/er.2016-1078 · Cited by 67
DeNicola, M., Du, J., Wang, Z., Yano, N., Zhang, L., Wang, Y., Qin, G., Zhuang, S., & Zhao, T. C. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00109.2014 · Cited by 63
Glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide: new advances
Asmar, M., & Holst, J. J. (2010) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3283339051 · Cited by 60
Pandey, S., Mangmool, S., & Parichatikanond, W. (2023) · Pharmaceuticals · doi:10.3390/ph16060836 · Cited by 61
Shao, W., Wang, Z., Ip, W., Chiang, Y., Xiong, X., Chai, T., Xu, C. K., Wang, Q., & Jin, T. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00600.2012 · Cited by 58
The entero-insular axis: implications for human metabolism
Ranganath, L. R. (2007) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2008.008 · Cited by 58
Zhao, T., Chen, H., Cheng, C., Zhang, J., Yan, Z., Kuang, J., Kong, F., Li, C., & Lu, Q. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109224 · Cited by 52
Patti, A. M., Nikolić, D., Magán‐Fernández, A., Giglio, R. V., Castellino, G., Chianetta, R., Citarrella, R., Corrado, E., Provenzano, F., Provenzano, V., et al. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.02.006 · Cited by 58
Investigation of the haemodynamic effects of exenatide in healthy male subjects
Mendis, B., Simpson, E., MacDonald, I., & Mansell, P. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04214.x · Cited by 56
Future perspectives on glucagon-like peptide-1, diabetes and cardiovascular risk
Mannucci, E., & Rotella, C. M. (2008) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2008.08.002 · Cited by 57
Do Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Cause Heart Failure?
Clifton, P. M. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.10.009 · Cited by 55
GLP-1 Agonists and Dipeptidyl-Peptidase IV Inhibitors
Gallwitz, B. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-17214-4_3 · Cited by 56
Holst, J. J., Albrechtsen, N. J. W., ROSENKILDE, M. M., & Deacon, C. F. (2019) · Comprehensive physiology · doi:10.1002/cphy.c180013 · Cited by 72
GLP-1 (9–36) Amide Metabolite Suppression of Glucose Production in Isolated Mouse Hepatocytes
Tomás, E., Stanojevic, V., & Habener, J. F. (2010) · Hormone and Metabolic Research · doi:10.1055/s-0030-1253421 · Cited by 53
Tomás, E., Stanojevic, V., McManus, K., Khatri, A., Everill, P., Bachovchin, W. W., & Habener, J. F. (2015) · Diabetes · doi:10.2337/db14-1708 · Cited by 54
Mosenzon, O., Raz, I., Scirica, B. M., Hirshberg, B., Stahre, C., Steg, P. G., Davidson, J. A., Öhman, P., Price, D. L., Frederich, B., et al. (2013) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2413 · Cited by 51
Ossum, A. M., van Deurs, U., Engstrøm, T., Jensen, J. S., & Treiman, M. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.06.004 · Cited by 51
Beyond Glycemic Control in Diabetes Mellitus: Effects of Incretin-Based Therapies on Bone Metabolism
Ceccarelli, E., Guarino, E., Merlotti, D., Patti, A., Gennari, L., Nuti, R., & Dotta, F. (2013) · Frontiers in Endocrinology · doi:10.3389/fendo.2013.00073 · Cited by 51
Metadata
- Authors
- Nikolaidis, L. A., Elahi, D., Shen, Y.-T., & Shannon, R. P.
- Affiliations
- Allegheny General Hospital (US)
- Venue
- American Journal of Physiology-Heart and Circulatory Physiology
- Publisher
- American Physiological Society
- Published
- 2005-12
- Volume
- 289
- Issue
- 6
- Pages
- H2401-H2408
- ISSN
- 0363-6135 (ISSN-L)
- 1522-1539
- OpenAlex
- W2169976140
- Cited by
- 274
- References
- 27
- Citations by year
- 2025: 4 · 2024: 5 · 2023: 4 · 2022: 8 · 2021: 4 · 2020: 5 · 2019: 12 · 2018: 12 · 2017: 8 · 2016: 19 · 2015: 15 · 2014: 29 · 2013: 22 · 2012: 26
- FWCI
- 6.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Physiology-Heart and Circulatory Physiology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (7r01da010480-09, 5r01ag023125-05)
- National Institute on Aging (AG-023125)
- National Institute on Drug Abuse (DA 10480)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- glucagon-like peptide-1, GLP-1(7-36), dipeptidyl peptidase IV, dilated cardiomyopathy, pacing-induced cardiomyopathy, myocardial glucose uptake, myocardial insulin resistance, left ventricular function, hemodynamics, cardiac output, myocardial substrate metabolism, hyperinsulinemic-euglycemic clamp
- MeSH terms
- Animals, Blood Pressure, Cardiomyopathy, Dilated, Consciousness, Coronary Circulation, Dogs, Dose-Response Relationship, Drug, Glucagon-Like Peptides, Female, Glucagon, Glucose, Heart, Heart Ventricles, Male, Myocardium, Peptide Fragments, Peptides, Stroke Volume, Treatment Outcome, Ventricular Dysfunction, Left, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
